Concepts (90)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Small Molecule Libraries | 6 | 2025 | 129 | 1.310 |
Why?
|
| Piperazines | 2 | 2022 | 265 | 1.240 |
Why?
|
| Protease Inhibitors | 2 | 2022 | 95 | 0.830 |
Why?
|
| Morpholines | 1 | 2024 | 66 | 0.810 |
Why?
|
| Diamines | 1 | 2022 | 8 | 0.730 |
Why?
|
| Stereoisomerism | 4 | 2024 | 106 | 0.670 |
Why?
|
| Drug Discovery | 2 | 2024 | 179 | 0.660 |
Why?
|
| DNA | 4 | 2024 | 1399 | 0.660 |
Why?
|
| Drug Design | 1 | 2021 | 156 | 0.640 |
Why?
|
| Molecular Structure | 4 | 2024 | 315 | 0.550 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2026 | 633 | 0.460 |
Why?
|
| Macrocyclic Compounds | 1 | 2015 | 14 | 0.450 |
Why?
|
| Epoprostenol | 1 | 2015 | 33 | 0.450 |
Why?
|
| Esters | 2 | 2024 | 29 | 0.390 |
Why?
|
| Molecular Conformation | 3 | 2021 | 96 | 0.330 |
Why?
|
| Proto-Oncogene Proteins c-myc | 2 | 2025 | 188 | 0.240 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2026 | 94 | 0.240 |
Why?
|
| Structure-Activity Relationship | 3 | 2024 | 552 | 0.230 |
Why?
|
| Models, Molecular | 2 | 2021 | 1064 | 0.220 |
Why?
|
| Activin Receptors, Type I | 1 | 2024 | 34 | 0.210 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2024 | 49 | 0.210 |
Why?
|
| Amino Acids | 2 | 2024 | 566 | 0.210 |
Why?
|
| Proteolysis | 1 | 2025 | 200 | 0.200 |
Why?
|
| Contraceptive Agents, Male | 1 | 2024 | 34 | 0.200 |
Why?
|
| Contraception | 1 | 2024 | 61 | 0.200 |
Why?
|
| Pain | 1 | 2026 | 450 | 0.200 |
Why?
|
| Endometriosis | 1 | 2026 | 176 | 0.190 |
Why?
|
| beta-Lactamase Inhibitors | 1 | 2023 | 62 | 0.190 |
Why?
|
| Acetic Acid | 1 | 2022 | 17 | 0.180 |
Why?
|
| Oleic Acid | 1 | 2022 | 16 | 0.180 |
Why?
|
| Combinatorial Chemistry Techniques | 1 | 2021 | 15 | 0.170 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 7 | 0.160 |
Why?
|
| Fluorenes | 1 | 2020 | 7 | 0.160 |
Why?
|
| Spliceosomes | 1 | 2021 | 47 | 0.160 |
Why?
|
| Genetic Engineering | 1 | 2021 | 161 | 0.160 |
Why?
|
| Enzyme Activation | 1 | 2021 | 576 | 0.160 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1618 | 0.160 |
Why?
|
| Neurogenesis | 1 | 2022 | 206 | 0.160 |
Why?
|
| Immunity | 1 | 2021 | 178 | 0.150 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2022 | 318 | 0.150 |
Why?
|
| Virus Replication | 1 | 2021 | 608 | 0.140 |
Why?
|
| Benzoquinones | 1 | 2017 | 20 | 0.130 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2021 | 280 | 0.130 |
Why?
|
| Lactams, Macrocyclic | 1 | 2017 | 33 | 0.130 |
Why?
|
| Peptides | 1 | 2020 | 708 | 0.130 |
Why?
|
| Hippocampus | 1 | 2022 | 806 | 0.120 |
Why?
|
| Antiviral Agents | 1 | 2022 | 807 | 0.120 |
Why?
|
| Cells, Cultured | 1 | 2021 | 2885 | 0.120 |
Why?
|
| Antineoplastic Agents | 1 | 2025 | 1826 | 0.110 |
Why?
|
| Crystallography, X-Ray | 1 | 2015 | 364 | 0.100 |
Why?
|
| Animals | 6 | 2026 | 33912 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2023 | 2596 | 0.090 |
Why?
|
| Proteins | 1 | 2014 | 1006 | 0.070 |
Why?
|
| Neurons | 1 | 2017 | 1979 | 0.060 |
Why?
|
| Mice | 4 | 2026 | 18301 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2025 | 3748 | 0.060 |
Why?
|
| Activin Receptors, Type II | 1 | 2024 | 30 | 0.050 |
Why?
|
| Humans | 8 | 2026 | 131163 | 0.050 |
Why?
|
| Blood-Testis Barrier | 1 | 2024 | 14 | 0.050 |
Why?
|
| Ubiquitination | 1 | 2025 | 173 | 0.050 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2025 | 241 | 0.050 |
Why?
|
| beta-Lactams | 1 | 2023 | 56 | 0.050 |
Why?
|
| Penicillins | 1 | 2023 | 154 | 0.050 |
Why?
|
| Luciferases, Firefly | 1 | 2022 | 11 | 0.050 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2025 | 354 | 0.050 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2022 | 18 | 0.050 |
Why?
|
| Testis | 1 | 2024 | 389 | 0.040 |
Why?
|
| beta-Lactamases | 1 | 2023 | 211 | 0.040 |
Why?
|
| Solutions | 1 | 2020 | 50 | 0.040 |
Why?
|
| RNA, Double-Stranded | 1 | 2021 | 56 | 0.040 |
Why?
|
| Ligands | 1 | 2022 | 481 | 0.040 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2023 | 859 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2024 | 4686 | 0.040 |
Why?
|
| Gene Amplification | 1 | 2021 | 219 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2021 | 249 | 0.040 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 101 | 0.040 |
Why?
|
| Introns | 1 | 2021 | 278 | 0.040 |
Why?
|
| RNA Splicing | 1 | 2021 | 235 | 0.040 |
Why?
|
| Molecular Targeted Therapy | 1 | 2021 | 386 | 0.030 |
Why?
|
| Cell Proliferation | 1 | 2022 | 2465 | 0.030 |
Why?
|
| Apoptosis | 1 | 2021 | 1827 | 0.030 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2014 | 43 | 0.030 |
Why?
|
| Tubulin | 1 | 2014 | 76 | 0.030 |
Why?
|
| 14-3-3 Proteins | 1 | 2014 | 56 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 165 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 157 | 0.020 |
Why?
|
| Protein Binding | 1 | 2014 | 1652 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2017 | 1928 | 0.020 |
Why?
|
| Female | 2 | 2026 | 70963 | 0.020 |
Why?
|
| Male | 1 | 2024 | 64957 | 0.010 |
Why?
|